scholarly journals Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: A prospective cohort study

2019 ◽  
Vol 61 ◽  
pp. 42-47 ◽  
Author(s):  
Yves Collin ◽  
Alex Paré ◽  
Assia Belblidia ◽  
Richard Létourneau ◽  
Marylène Plasse ◽  
...  
Keyword(s):  
Cohort Study ◽  
Portal Vein ◽  
Liver Metastases ◽  
Portal Vein Embolization ◽  
Prospective Cohort ◽  
Colorectal Liver Metastases ◽  
Cancer Recurrence ◽  
Term Survival ◽  
Risk Of Cancer

scholarly journals Oncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 200
Author(s):  
Salah Khayat ◽  
Gianluca Cassese ◽  
François Quenet ◽  
Christophe Cassinotto ◽  
Eric Assenat ◽  
...  
Keyword(s):  
Portal Vein ◽  
Liver Metastases ◽  
Portal Vein Embolization ◽  
Colorectal Liver Metastases ◽  
Future Liver Remnant ◽  
Small Sample ◽  
Right Hepatectomy ◽  
Liver Remnant ◽  
Oncological Outcomes ◽  
Extended Right Hepatectomy

Colorectal liver metastases (CRLM) are the major cause of death in patients with colorectal cancer (CRC). The cornerstone treatment of CRLM is surgical resection. Post-operative morbidity and mortality are mainly linked to an inadequate future liver remnant (FLR). Nowadays preoperative portal vein embolization (PVE) is the most widely performed technique to increase the size of the future liver remnant (FLR) before major hepatectomies. One method recently proposed to increase the FLR is liver venous deprivation (LVD), but its oncological impact is still unknown. The aim of this study is to report first short- and long-term oncological outcomes after LVD in patients undergoing right (or extended right) hepatectomy for CRLM. Seventeen consecutive patients undergoing LVD between July 2015 and May 2020 before an (extended) right hepatectomy were retrospectively analyzed from an institutional database. Post-operative and follow-up data were analyzed and reported. Primary outcomes were 1-year and 3-year overall survival (OS) and hepatic recurrence (HR). Postoperative complications occurred in 8 patients (47%). No deaths occurred after surgery. HR occurred in 9 patients (52.9%). 1-year and 3-year OS were 87% (95% confidence interval [CI]: ±16%) and 60.3%, respectively (95% CI: ±23%). Median Disease-Free Survival (DFS) was 6 months (CI 95%: 4.7–7.2). With all the limitations of a retrospective study with a small sample size, LVD showed similar oncological outcomes compared to literature reports for Portal Vein Embolization (PVE).

Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography

2014 ◽  
Vol 110 (3) ◽  
pp. 313-319 ◽  
Author(s):  
Reyad A. Abbadi ◽  
Umar Sadat ◽  
Asif Jah ◽  
Raaj K. Praseedom ◽  
Neville V. Jamieson ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Emission Tomography ◽  
Term Survival ◽  
Long Term Survival ◽  
Positron Emission

scholarly journals P-166 Re-hepatectomy is a predictor of long-term survival in patients that recur after liver resection of colorectal liver metastases

2016 ◽  
Vol 27 ◽  
pp. ii49
Author(s):  
M. Marques ◽  
H.S. de Castro Ribeiro ◽  
W.L. Costa ◽  
A.L. Diniz ◽  
A. Godoy ◽  
...  
Keyword(s):  
Liver Resection ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Pros and Cons of Portal Vein Embolization With Hematopoietic Stem Cells Application in Colorectal Liver Metastases Surgery

In Vivo ◽  
2020 ◽  
Vol 34 (5) ◽  
pp. 2919-2925
Author(s):  
VLADISLAV TRESKA ◽  
JAN BRUHA ◽  
VACLAV LISKA ◽  
JAKUB FICHTL ◽  
KRISTYNA PROCHAZKOVA ◽  
...  
Keyword(s):  
Stem Cells ◽  
Portal Vein ◽  
Hematopoietic Stem Cells ◽  
Liver Metastases ◽  
Portal Vein Embolization ◽  
Colorectal Liver Metastases ◽  
Hematopoietic Stem ◽  
Pros And Cons

scholarly journals FDG-PET Improves Management of Patients with Colorectal Liver Metastases Allocated for Local Treatment: A Consecutive Prospective Study

2007 ◽  
Vol 96 (3) ◽  
pp. 209-213 ◽  
Author(s):  
M. Sørensen ◽  
F. V. Mortensen ◽  
M. Høyer ◽  
H. Vilstrup ◽  
S. Keiding ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Fdg Pet ◽  
Colorectal Liver Metastases ◽  
Imaging Modality ◽  
Treatment Plan ◽  
Local Treatment ◽  
Liver Lesions ◽  
Term Survival ◽  
Pre Treatment

Background and Aim: Colorectal cancer is a common cancer in the Nordic countries and 50% of the patients develop liver metastases. Liver resection may result in long term survival. Proper staging is therefore essential and CT is the standard imaging modality. We examined whether additional FDG-PET improves therapeutic management of patients with colorectal liver metastases. Patients and Methods: Fifty-four consecutive patients were enrolled. Each patient had a treatment plan made based on our standard evaluation. The patients then had a PET scan and the treatment plan was re-evaluated, taking these results into account. Results: In 76% of the cases, PET did not change the treatment plan due to complete concordance with CT. In another 19% of the cases, the plan was altered due to finding of more liver lesions by PET than by CT (four patients), fewer or no liver lesions (three patients), and extrahepatic lesions not visible on CT (three patients). In 5% of the cases, non-concordance between PET and CT did not change the therapeutic plan. Conclusion: Pre-treatment FDG-PET, used supplementary to CT, improved the treatment plan in one fifth of the patients with colorectal liver metastases.

Sign in / Sign up

Export Citation Format

Share Document